Belantamab mafodotin, lenalidomide, and dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin‐associated ocular adverse events and their impact on daily functioning from the part 1 of a pha

Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Nikolaos Kanellias, Evangelos Eleutherakis‐Papaiakovou, Maria Roussou, Giorgos Psarros, Efstathios Kastritis, Meletios A. Dimopoulos, Evangelos Terpos

doi:HTTPS://DOI.ORG/10.1002/ajh.27219

Belantamab mafodotin, lenalidomide, and dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin‐associated ocular adverse events and their impact on daily functioning from the part 1 of a pha

Authors: Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Nikolaos Kanellias, Evangelos Eleutherakis‐Papaiakovou, Maria Roussou, Giorgos Psarros, Efstathios Kastritis, Meletios A. Dimopoulos, Evangelos Terpos

Published: 2024-01-25

DOI: HTTPS://DOI.ORG/10.1002/ajh.27219

Keywords: No keywords found.

Abstract:
No abstract found.

Source: